Viking Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €497.12M +227.9% -€159.65M -53.8% -32.1% +2.0 pp N/A N/A
    (estimated) €151.59M +1,592.6% -€345.31M -7.6% -227.8% +39 pp N/A N/A
    (estimated) €8.96M +46.4% -€373.57M +21.3% -4,171.1% +8.7 pp N/A N/A
    (estimated) €6.12M +∞% -€308.03M +31.9% -5,036.8% -50 pp -€301.37M +33.5% -4,927.9% -49 pp
    (estimated) €0.00 +NaN% -€233.61M +149.1% N/A -€225.78M +201.5% N/A
    €0.00 +NaN% -€93.79M +28.0% N/A -€74.88M +19.6% N/A
    €0.00 +NaN% -€73.26M +27.5% N/A -€62.59M +51.6% N/A
    €0.00 +NaN% -€57.47M +24.8% N/A -€41.28M +1.7% N/A
    €0.00 +NaN% -€46.06M +49.8% N/A -€40.59M +118.5% N/A
    €0.00 +NaN% -€30.75M +39.8% N/A -€18.57M -12.0% N/A
    €0.00 +NaN% -€21.99M +16.8% N/A -€21.11M +32.0% N/A
    €0.00 +NaN% -€18.82M +7.2% N/A -€16.00M +27.1% N/A
    €0.00 +NaN% -€17.55M +39.7% N/A -€12.59M +33.3% N/A
    €0.00 +NaN% -€12.57M -37.1% N/A -€9.44M +26.8% N/A
    €0.00 +NaN% -€19.96M +6.9% N/A -€7.45M +448.7% N/A
    €0.00 +NaN% -€18.67M +14,863.9% N/A -€1.36M +1,934.2% N/A
    €0.00 +NaN% -€124.74K +32,830.5% N/A -€66.73K +39,017.5% N/A
    €0.00 -€378.80 N/A -€170.59 N/A

    Notifications